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deforming the sequential activity maps using registered 
sequential SPECT-CT scans and with the parallelogram 
method. In 9 out of 11 cases the Olinda/EXM calculations of 
average dose absorbed by the kidneys was below the dose 
calculated by Raydose (range [8,51]%). In 2 cases the kidney 
average dose, as calculated with the Olinda/EXM method, 
were below the dose calculated with Raydose (-6,-26)%. DVHs 
and 3D dose maps provided valuable information regarding 
the uniformity of the dose distribution which would have 
been otherwise missed with an organ level approach.  
Conclusions: Following the experience obtained in this pilot 
study we conclude that it is feasible to implement in routine 
delivery of PRRT therapy patient specific 3D dose calculation 
using Raydose. Our workflow included deformable image 
registration to accurately account for changes in both 
patients anatomy and activity distribution during the course 
of the therapy. Work is in progress to use Raydose to 
optimise PRRT treatments in terms of fractionation, 
combination of isotopes and correlation with toxicity data.  
 
PO-0895   
3D transperineal ultrasound image guidance methods for 
prostate SBRT radiotherapy treatment 
B.J. Salter1, M. Szegedi1, J. Tward1, H. Zhao1, V. Sarkar1, P. 
Rassiah-Szegedi1, L. Huang1, J. Huang1 
1University of Utah (Huntsman Cancer Hospital), Radiation 
Oncology, Salt Lake City, USA  
 
Purpose/Objective: A second generation 3D ultrasound 
image guidance (USIG) system (Clarity, Elekta Inc), which 
allows for transperineal (TP) localization and intra-fractional 
tracking of the prostate has been evaluated for use in 
stereotactic body radiation therapy (SBRT) of the prostate at 
our institution. Here we describe our implementation of a 
prostate SBRT TP USIG protocol.  
Materials and Methods: After the development of an initial 
clinical USIG based workflow for standard fractionation 
treatment, we extended the workflow to allow for increased 
positional verification required for SBRT. Our SBRT treatment 
protocol gives 36.25 Gy in 5 fractions, every other day and 
utilizes USIG to ensure target coverage. The planning target 
volume (PTV) is defined as the CTV plus a 3 mm margin 
posteriorly and 5 mm in all other dimensions.  Patient 
alignment has to be approved by a physicist and a physician, 
both of whom have to be experienced in reading US images. 
During intra-fractional US-tracking, corrective action is taken 
if the target migrates more than 3 mm for more than 5 
seconds in any of three orthogonal coordinates. Patients were 
positioned according to SBRT protocol and aligned to skin 
marks using treatment room lasers. TP USIG was performed 
and shifts from tattoo were performed and recorded. For 
purpose of redundant verification, a transabdominal (TA) 
USIG was performed (BAT, Nomos Inc.) while TP USIG 
tracking was on. Treatment was conducted using TP USIG 
tracking. 
Results: A total of 57 fractions delivered to 11 prostate 
cancer patients were retrospectively analyzed for workflow 
performance, patient motion and agreement between two US 
image guidance devices (TA and TP). The mean of initial USIG 
shifts from skin marks based on TP positioning for all 11 
patients was 0.24, 1.25, and -4.38 mm in left-right (LR), 
anterior-posterior (AP), and superior-inferior (SI) directions 
respectively. The average difference between the two US 
systems (TP vs TA) for all patients was -0.05, -0.02, and -0.04 
mm in LR, AP and SI directions respectively. The respective 
standard deviations were 0.14, 0.34 and 0.27 mm. Patient 
alignment was corrected if indicated by tracking. Intra-
fractional tracking data was analyzed and will be presented 
(see Image 1). 
 
 
 
Conclusions: 11 prostate SBRT patients treated in our clinic 
were localized using two USIG systems which showed average 
agreement to less than 0.5 mm in all three principle 
directions (LR, AP, SI). Intra-fraction tracking allowed us to 
reduce treatment planning margins to 3 mm posteriorly and 5 
mm elsewhere, due to the ability to track and correct for 
motion during treatment. 
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Purpose/Objective: ProtecT is a phase 3 clinical trial [1] 
comparing prostate cancer mortality for patients with 
clinically localised prostate cancer randomly assigned to 
active monitoring, radical prostatectomy or 3D conformal 
external beam radiotherapy.  
Trial results are anticipated for 2016 and the purpose of this 
work is to assess the quality of treatment plans produced for 
participants randomised to receive radiotherapy. 
Materials and Methods: 545 of the participants, recruited 
across 9 UK cities were randomised to receive radiotherapy. 
3D conformal external beam radiotherapy was used to deliver 
74Gy to the isocentre in 2Gy fractions in 2 phases. During 
phase 1 a dose of 56Gy was prescribed to a target volume 
including prostate and seminal vesicles and during phase 2 a 
dose of 18Gy is prescribed to a target volume surrounding 
prostate only. To ensure consistency and comparability of 
radiotherapy between centres a detailed radiotherapy 
protocol was developed. To assess the quality of radiotherapy 
plans, 13 quantities were measured and a deviation recorded 
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if the corresponding objective was not met (Table 1). 
Radiotherapy plan data was submitted by treatment centres 
in DICOM or RTOG format and 52 randomly selected plans 
were processed with the Computational Environment for 
Radiotherapy Research (CERR) software [2] which enabled i) 
outlining of target and organ-at-risk structures and ii) dose 
distribution and dose volume histograms to be assessed.  
 
 
Table 1: Summary of quantities assessed during review of 
radiotherapy plans.  
 
Results: The total number of deviations identified was ~11% 
of the total possible. 81% of plans had two or fewer 
deviations indicating good adherence to the trial protocol 
(Figure 1).  64% of deviations were related to the rectum. 
There were 5 dose volume objectives associated with the 
rectum and it was recognised that failure to meet one rectal 
constraint generally corresponded with further deviations.  
All patient plans used 3 or 4 gantry angles in a 'pelvic-brick' 
beam distribution with or without the posterior beam. No 
patient failed the ICRU Max D1.8cc constraint. 
 
Figure 1: Histogram showing number of deviations recorded 
per plan reviewed. The type of deviation recorded is 
indicated by the colour of the bars. 
Conclusions: Deviation from the clinical trial protocol has 
the potential to confound the study question and quality 
assurance is therefore essential when comparing different 
treatments. Our analysis of a subset of the radiotherapy plans 
demonstrates good understanding and adherence to the 
ProtecT protocol.  
This study is supported by the UK National Institute for 
Health Research (NIHR) Health Technology Assessment 
(HTA) Programme, HTA 96/20/99; ISRCTN20141297’.  
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Purpose/Objective: Quality assurance (QA) of volumetric-
modulated radiotherapy (VMAT) has developed substantially 
in recent years. One of the most important roles of 
dosimetric verification is to detect errors in plan 
implementation on the treatment machine. Such errors 
include incorrect mechanical settings, differences in doses, 
and shifts in the multileaf collimators. To verify that the 
treatment plan is correct, it is necessary to use proper 
measuring tools (e.g., 2D and 3D detector arrays) in addition 
to an analytical method (e.g., gamma method) that includes 
tolerance and passing criteria that are sufficiently sensitive 
to achieve reliable results. The detector arrays, however, are 
limited by their resolution. Understanding the limitations of 
these devices is therefore crucial. The aim of the work was 
to characterize the sensitivity to induced errors of 2D-arrays 
for FFF prostate plan verification. 
Materials and Methods: The new 2D ion chamber array 1500 
and the well-known arrays, seven29 and SRS1000 with 
rotational phantom cylindrical Octavius® 4D and Verisoft 6.0 
software (PTW, Freiburg, Germany) were used to determine 
the sensitivity to induced errors. Measured and calculated 
dose distributions of VMAT high-fractionated FFF prostate 
plans were compared using the 3D gamma analysis by global 
(maximum) and local dose methods with a 5% threshold for 
various tolerance parameters DTA [mm] and DD [%] were 1.0; 
1.5; 2.0; 2.5; 3.0; 3.5. The sensitivity of the 2D-arrays was 
tested using the errors inserted into VMAT plan: a collimator 
rotation angle (1; 2; 3 degree), dose (difference in %: 0.5; 
1.0; 2.0) and MU errors (5MU was missing in each field at the 
end of gantry position). Later, the erroneous plans were 
compared to measure error-free dose distributions on arrays 
on a linear accelerator (TrueBeam, Varian). 
Results: The results for each of the arrays analyzed differed 
and were strictly dependent on the resolution of the 
detector. The results obtained were as follow: for gamma 
criteria 2/2 (DTA[mm]/DD[%]): SRS1000 (L99.5; G99.9), 1500 
(L95.8; G99.0), 729 (L92.2; G97.0); for 3/3: SRS1000 (L99.0; 
G100.0), 1500 (L99.4; G100.0), 729 (L98.9; G99.7). The 
highest differences were observed for inserted errors: coll 3º, 
dose lowered by 2.0% and MU errors (L2/2; 1500): 94.0; 89.0; 
95.0, respectively. The sensitivity of arrays to errors was 
presented in Fig.1. 
